menu search

DVA / DaVita (DVA) to Report Q3 Earnings: What's in the Offing?

DaVita (DVA) to Report Q3 Earnings: What's in the Offing?
Improvement in U.S. dialysis treatments per day and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the third quarter. Read More
Posted: Nov 3 2023, 13:32
Author Name: Zacks Investment Research
Views: 072433

DVA News  

DaVita (DVA) to Report Q3 Earnings: What's in the Offing?

By Zacks Investment Research
November 3, 2023

DaVita (DVA) to Report Q3 Earnings: What's in the Offing?

Improvement in U.S. dialysis treatments per day and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the third quarter. more_horizontal

Buffett's Bullish Bets: 3 Stocks Where Warren Has At Least a 25% Stake

By InvestorPlace
October 24, 2023

Buffett's Bullish Bets: 3 Stocks Where Warren Has At Least a 25% Stake

We know Warren Buffett likes to make big bets on business. Apple (NASDAQ: AAPL ) is famously one of the largest Warren Buffett stocks, accounting for more_horizontal

DaVita Inc. Schedules 3rd Quarter 2023 Investor Conference Call

By PRNewsWire
October 17, 2023

DaVita Inc. Schedules 3rd Quarter 2023 Investor Conference Call

DENVER , Oct. 17, 2023 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss third quar more_horizontal

DaVita says news of Ozempic's potential in treating kidney disease may have only limited impact for patients, says further studies will be needed

By Market Watch
October 12, 2023

DaVita says news of Ozempic's potential in treating kidney disease may have only limited impact for patients, says further studies will be needed

Dialysis company DaVita Inc. DVA, -16.86% issued a statement on Thursday in response to the news Wednesday from Novo Nordisk that its Ozempic treatmen more_horizontal

DaVita says Ozempic's early success in kidney trial to have 'limited application'

By Reuters
October 12, 2023

DaVita says Ozempic's early success in kidney trial to have 'limited application'

Dialysis firm DaVita said on Thursday it believes that early success of Novo Nordisk's diabetes drug Ozempic in kidney disease trial will have "limite more_horizontal

Why Dialysis Stocks Plunged Today

By The Motley Fool
October 11, 2023

Why Dialysis Stocks Plunged Today

Novo Nordisk shares rallied after it announced it will stop its FLOW trial nearly a year earlier than expected after positive feedback on interim data more_horizontal

Ozempic Alert: New Trial Causes DaVita (DVA) Stock to Plunge 20%

By InvestorPlace
October 11, 2023

Ozempic Alert: New Trial Causes DaVita (DVA) Stock to Plunge 20%

Ozempic may find yet another clinical use. The drug, developed by Danish pharmaceutical giant Novo Nordisk (NYSE: NVO ), has been making waves through more_horizontal

Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term

By Zacks Investment Research
October 11, 2023

Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Pre more_horizontal


Search within

Pages Search Results: